ATP5IF1 and neoplasm: These findings reveal previously unrecognized roles of tumor suppressor miR-148b-5p in GC development, suggesting the miR-148b-5p/ATPIF1 axis as a therapeutic target and potential prognostic biomarker for patients with GC.